Vector systems for prenatal gene therapy: Principles of retrovirus vector design and production

Methods in Molecular Biology

Volumn 891, Issue , 2012, Pages 85-107

  Howe, Steven J ^a   Chandrashekran, Anil ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

293T; Concentration; Envelope; Gammaretrovirus; HIV; Lentivirus; MLV; Packaging cell line; Phoenix packaging cell lines; Preparation; Pseudotype; Retrovirus; SIN; Targeting; Titration; WPRE

Indexed keywords

CELL SURFACE PROTEIN; CHLOROQUINE; ENVELOPE PROTEIN; INITIATION FACTOR 1A; LENTIVIRUS VECTOR; MEMBRANE PROTEIN; MICRORNA; RETROVIRUS VECTOR;

5' UNTRANSLATED REGION; ARTICLE; CELL TYPE; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; DNA MODIFICATION; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LENTIVIRINAE; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; POLYADENYLATION; PREGNANCY; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN TRANSPORT; PSEUDOTYPING; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INACTIVATION; VIRUS STRAIN; WOODCHUCK HEPATITIS VIRUS;

GAMMARETROVIRUS; LENTIVIRUS; RETROVIRIDAE;

EID: 84934437401     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-873-3_5     Document Type: Article

References (60)

1. Suerth JD, Maetzig T, Galla M et al (2010) Self-inactivating alpharetroviral vectors with a split-packaging design. J Virol 84:6626-6635
2. Guntaka RV, Swamynathan SK (1998) Retroviral vectors for gene therapy. Indian J Exp Biol 36:539-545
3. Palu G, Parolin C, Takeuchi Y, Pizzato M (2000) Progress with retroviral gene vectors. Rev Med Virol 10:185-202
4. Naldini L, Blomer U, Gage FH et al (1996) Ef fi cient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93:11382-11388
5. Russell DW, Miller AD (1996) Foamy virus vectors. J Virol 70:217-222
6. Hacein-Bey-Abina S, Le DF, Carlier F, Bouneaud C et al (2002) Sustained correction of X-linked severe combined immunode fi ciency by ex vivo gene therapy. N Engl J Med 346: 1185-1193
7. Gaspar HB, Parsley KL, Howe S et al (2004) Gene therapy of X-linked severe combined immunode fi ciency by use of a pseudotyped gammaretroviral vector. Lancet 364:2181-2187
8. Aiuti A, Cattaneo F, Galimberti S et al (2009) Gene therapy for immunode fi ciency due to adenosine deaminase de fi ciency. N Engl J Med 360:447-458
9. Ott MG, Schmidt M, Schwarzwaelder K et al (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409
10. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823
11. Reiser J, Harmison G, Kluepfel-Stahl S et al (1996) Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A 93: 15266-15271
12. Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7(980-6):989
13. Dull T, Zufferey R, Kelly M et al (1998) A thirdgeneration lentivirus vector with a conditional packaging system. J Virol 72:8463-8471
14. Naldini L, Blomer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267
15. Follenzi A, Ailles LE, Bakovic S et al (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-222
16. Zennou V, Petit C, Guetard D et al (2000) HIV-1 genome nuclear import is mediated by a central DNA fl ap. Cell 101:173-185
17. Demaison C, Parsley K, Brouns G et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunode fi ciency [correction of immunode fi ciency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813
18. Zufferey R, Nagy D, Mandel RJ et al (1997) Multiply attenuated lentiviral vector achieves ef fi cient gene delivery in vivo. Nat Biotechnol 15:871-875
19. Schwickerath O, Brouns G, Thrasher A et al (2004) Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD. J Gene Med 6:603-615
20. Dougherty JP, Temin HM (1986) High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol 6:4387-4395
21. Amendola M, Venneri MA, Bif fi A et al (2005) Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 23:108-116
22. Fux C, Langer D, Kelm JM (2004) Newgeneration multicistronic expression platform: pTRIDENT vectors containing size-optimized IRES elements enable homing endonucleasebased cistron swapping into lentiviral expression vectors. Biotechnol Bioeng 86:174-187
23. Pizzato M, Franchin E, Calvi P et al (1998) Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther 5:1003-1007
24. Chinnasamy D, Milsom MD, Shaffer J et al (2006) Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J 3:14
25. Chinnasamy N, Shaffer J, Chinnasamy D (2009) Production of multicistronic HIV-1 based lentiviral vectors. Methods Mol Biol 515:137-150
26. Zhang XY, La RV, Reiser J (2004) Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modi fi ed RD114 envelope glycoproteins. J Virol 78:1219-1229
27. Donello JE, Loeb JE, Hope TJ (1998) Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 72:5085-5092
28. Zavada J, Zazadova Z, Malir A, Kocent A (1972) VSV pseudotype produced in cell line derived from human mammary carcinoma. Nat New Biol 240:124-125
29. Zavada J (1976) Viral pseudotypes and phenotypic mixing. Arch Virol 50:1-15
30. Battini JL, Heard JM, Danos O (1992) Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J Virol 66:1468-1475
31. Rahim AA, Wong AM, Howe SJ et al (2009) Ef fi cient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 16:509-520
32. Mazarakis ND, Azzouz M, Rohll JB et al (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10:2109-2121
33. Russell SJ, Cosset FL (1999) Modifying the host range properties of retroviral vectors. J Gene Med 1:300-311
34. Morling FJ, Peng KW, Cosset FL, Russell SJ (1997) Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 234:51-61
35. Cosset FL, Morling FJ, Takeuchi Y et al (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-6322
36. Valsesia-Wittmann S, Morling FJ, Nilson BH et al (1996) Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 70:2059-2064
37. Kasahara N, Dozy AM, Kan YW (1994) Tissuespeci fi c targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376
38. Jeetendra E, Robison CS, Albritton LM, Whitt MA (2002) The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion. J Virol 76:12300-12311
39. Zhang XY, Kutner RH, Bialkowska A et al (2010) Cell-speci fi c targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus. Retrovirology 7:3
40. Morizono K (2005) Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11:346-352
41. Pariente N, Mao SH, Morizono K, Chen IS (2008) Ef fi cient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J Gene Med 10:242-248
42. Buchholz CJ, Muhlebach MD, Cichutek K (2009) Lentiviral vectors with measles virus glycoproteins-dream team for gene transfer? Trends Biotechnol 27:259-265
43. Szecsi J, Drury R, Josserand V et al (2006) Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 14: 735-744
44. Hammarstedt M, Wallengren K, Pedersen KW et al (2000) Minimal exclusion of plasma membrane proteins during retroviral envelope formation. Proc Natl Acad Sci U S A 97:7527-7532
45. Chandrashekran A, Gordon MY, Casimir C (2004) Targeted retroviral transduction of c-kit + hematopoietic cells using novel ligand display technology. Blood 104:2697-2703
46. Thornhill SI, Schambach A, Howe SJ et al (2008) Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunode fi ciency. Mol Ther 16:590-598
47. Charrier S, Dupre L, Scaramuzza S et al (2007) Lentiviral vectors targeting WASp expression to hematopoietic cells, ef fi ciently transduce and correct cells from WAS patients. Gene Ther 14:415-428
48. Ferrari G, Salvatori G, Rossi C et al (1995) A retroviral vector containing a muscle-speci fi c enhancer drives gene expression only in differentiated muscle fi bers. Hum Gene Ther 6: 733-742
49. Vile RG, Hart IR (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53:962-967
50. Vile RG, Hart IR (1994) Targeting of cytokine gene expression to malignant melanoma cells using tissue speci fi c promoter sequences. Ann Oncol 5(Suppl 4):59-65
51. Brown BD, Venneri MA, Zingale A et al (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12:585-591
52. Cosset FL, Takeuchi Y, Battini JL et al (1995) High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69:7430-7436
53. Loew R, Meyer Y, Kuehlcke K et al (2010) A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther 17:272-280
54. Kinsella TM, Nolan GP (1996) Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 7: 1405-1413
55. Rodrigues T, Alves A, Lopes A et al (2008) Removal of envelope protein-free retroviral vectors by anion-exchange chromatography to improve product quality. J Sep Sci 31: 3509-3518
56. Landazuri N, Le Doux JM (2006) Complexation with chondroitin sulfate C and Polybrene rapidly puri fi es retrovirus from inhibitors of transduction and substantially enhances gene transfer. Biotechnol Bioeng 93:146-158
57. Sastry L, Johnson T, Hobson MJ et al (2002) Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 9:1155-1162
58. Fehse B, Kustikova OS, Bubenheim M, Baum C (2004) Pois(s)on-it's a question of dose. Gene Ther 11:879-881
59. Lizee G, Aerts JL, Gonzales MI et al (2003) Real-time quantitative reverse transcriptasepolymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther 14:497-507
60. Delenda C (2004) Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med 6(Suppl 1):S125-S138